ArticleJournal of virology2002
Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 130 citations in OpenAlex.
- Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.The Journal of infectious diseases · 2016Trial
- A real-time killing assay to follow viral epitope presentation to CD8 T cells.Journal of immunological methods · 2013Trial
- A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.PloS one · 2011Trial
- Immunophenotypic alterations in acute and early HIV infection.Clinical immunology (Orlando, Fla.) · 2007Trial
- A live, attenuated recombinant West Nile virus vaccine.Proceedings of the National Academy of Sciences of the United States of America · 2006Trial
- Multi-layered Gag-specific immunodominant responses contribute to improved viral control in the CRF01_AE subtype of HIV-1-infected MSM subjects.BMC immunology · 2016Article
- Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.Nature · 2015Article
- Different antigen-processing activities in dendritic cells, macrophages, and monocytes lead to uneven production of HIV epitopes and affect CTL recognition.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- TCR affinity associated with functional differences between dominant and subdominant SIV epitope-specific CD8+ T cells in Mamu-A*01+ rhesus monkeys.PLoS pathogens · 2014Article
- Vertical T cell immunodominance and epitope entropy determine HIV-1 escape.The Journal of clinical investigation · 2013Article
- HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice.PloS one · 2013Article
- The T-cell response to HIV.Cold Spring Harbor perspectives in medicine · 2012Review
- Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications.Future virology · 2012Article
- High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection.Immunology and cell biology · 2012Article
- Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection.PloS one · 2012Article
- Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity.Journal of virology · 2011Article
- Limited immunogenicity of HIV CD8+ T-cell epitopes in acute Clade C virus infection.The Journal of infectious diseases · 2011Article
- Variable HIV peptide stability in human cytosol is critical to epitope presentation and immune escape.The Journal of clinical investigation · 2011Article
- Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals.Journal of virology · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses generated during acute infection play a critical role in the initial control of viremia. However, little is known about the viral T-cell epitopes targeted during acute infection or about their hierarchy in appearance and relative immunodominance over time. In this study, HIV-1-specific CD8+ T-cell responses in 18 acutely infected individuals expressing HLA-A3 and/or -B7 were characterized. Detailed analysis of CD8 responses in one such person who underwent treatment of acute infection followed by reexposure to HIV-1 through supervised treatment interruptions (STI) revealed recognition of only two cytotoxic T-lymphocyte (CTL) epitopes during symptomatic acute infection. HIV-1-specific CD8+ T-cell responses broadened significantly during subsequent exposure to the virus, ultimately targeting 27 distinct CTL epitopes, including 15 different CTL epitopes restricted by a single HLA class I allele (HLA-A3). The same few peptides were consistently targeted in an additional 17 persons expressing HLA-A3 and/or -B7 during acute infection. These studies demonstrate a consistent pattern in the development of epitope-specific responses restricted by a single HLA allele during acute HIV-1 infection, as well as persistence of the initial pattern of immunodominance during subsequent STI. In addition, they demonstrate that HIV-1-specific CD8+ T-cell responses can ultimately target a previously unexpected and unprecedented number of epitopes in a single infected individual, even though these are not detectable during the initial exposure to virus. These studies have important implications for vaccine design and evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.